論文

査読有り 国際誌
2020年10月

Osimertinib regressed an EGFR-mutant lung-adenocarcinoma bone-metastasis mouse model and increased long-term survival.

Translational oncology
  • Takashi Higuchi
  • ,
  • Norihiko Sugisawa
  • ,
  • Jun Ho Park
  • ,
  • Yu Sun
  • ,
  • Guangwei Zhu
  • ,
  • Norio Yamamoto
  • ,
  • Katsuhiro Hayashi
  • ,
  • Hiroaki Kimura
  • ,
  • Shinji Miwa
  • ,
  • Kentaro Igarashi
  • ,
  • Michael Bouvet
  • ,
  • Shree Ram Singh
  • ,
  • Hiroyuki Tsuchiya
  • ,
  • Robert M Hoffman

13
10
開始ページ
100826
終了ページ
100826
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1016/j.tranon.2020.100826

Bone is one of the most frequent metastatic sites in non-small cell lung cancer (NSCLC). Osimertinib, with and without bevacizumab (BV), has been investigated on advanced NSCLC patients. However, the efficacy of those drugs on bone metastasis of NSCLC has not been investigated. The human NSCLC cell line H1975, expressing red fluorescent protein (H1975-RFP), was orthotopically injected to the tibia of nude mice. The established mouse models were randomized into four treatment groups of nine mice: Control; BV alone; osimertinib alone; osimertinib and BV combination. The tumors were observed by non-invasive fluorescence imaging. Osimertinib, with or without BV, caused tumor regression, increased mouse survival, and bone remodeling in the bone metastasis models. These results suggest that osimertinib is a promising clinical option for NSCLS patients with bone metastasis.

リンク情報
DOI
https://doi.org/10.1016/j.tranon.2020.100826
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/32659740
PubMed Central
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356269

エクスポート
BibTeX RIS